Ipsen SA

Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

15 фев 2023 01:00:00 Источник Nasdaq GlobeNewswire

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

13 фев 2023 17:00:00 Источник Nasdaq GlobeNewswire

IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital

10 фев 2023 12:00:00 Источник Nasdaq GlobeNewswire

Ipsen presents strong full-year 2022 results and guidance for 2023

09 фев 2023 01:00:02 Источник Nasdaq GlobeNewswire